Silver and other metals in the treatment of gastrointestinal diseases

Current Medicinal Chemistry

Volumn 22, Issue 32, 2015, Pages 3695-3706

  Siczek, Krzysztof ^a,b   Zatorski, Hubert ^b   Fichna, Jakub ^b,c  

^a LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Colorectal cancer; Gastrointestinal tract; Inflammatory bowel diseases; Microbiota; Nanoparticles; Silver

Indexed keywords

CERIUM; COBALT; COPPER; GOLD; GOLD NANOPARTICLE; METAL DERIVATIVE; SILVER; SILVER DERIVATIVE; ZINC; COORDINATION COMPOUND;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL INFECTION; CANCER THERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CROHN DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HUMAN; ILEITIS; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LYMPHOCYTIC COLITIS; MICROSCOPIC COLITIS; NANOTECHNOLOGY; NONHUMAN; PEPTIC ULCER; PSEUDOMEMBRANOUS COLITIS; ULCERATIVE COLITIS; WOUND HEALING; CHEMISTRY; CLASSIFICATION; GASTROINTESTINAL DISEASES; MEDICINAL CHEMISTRY; TRENDS;

CHEMISTRY, PHARMACEUTICAL; COORDINATION COMPLEXES; COPPER; GASTROINTESTINAL DISEASES; HUMANS; SILVER;

EID: 84947907778     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666151001121439     Document Type: Article

References (89)

1. Hunter, P. The secret garden. The human digestive system is teeming with microbiotic life, but just how important are these interlopers for health and disease? EMBO Rep., 2009, 10, 1082-1086.
2. Prabhu, V.; Shivani, A. An overview of history, pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults. Ann. Med. Health Sci. Res., 2014, 4, 22-29.
3. Laine, L.; Curtis, S.P.; Cryer, B.; Kaur, A.; Cannon, C.P. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment. Pharmacol. Ther., 2010, 32, 1240-1248.
4. Vergara, M.; Catalan, M.; Gisbert, J.P.; Calvet, X. Metaanalysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther., 2005, 21, 1411-1418.
5. Shiotani, A.;Graham, D.Y. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med. Clin. North Am., 2002, 86, 1447-66.
6. McColl, K.E. Clinical practice. Helicobacter pylori infection. N. Engl. J. Med., 2010, 362, 1597-1604.
7. Dilauro, S.; Crum-Cianflone, N.F. Ileitis: when it is not Crohn's disease. Curr. Gastroenterol. Rep., 2010, 12, 249-258.
8. Sun, X.; Hirota, S.A. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol. Immunol., 2015, 63(2), 193-202.
9. Sobczak, M.; Fabisiak, A.; Murawska, N.; Wesołowska, E.; Wierzbicka, P.; Wlazłowski, M.; Wojcikowska, M.; Zatorski, H.; Zwolińska, M.; Fichna, J. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol. Rep., 2014, 66, 766-775.
10. Garud, S.; Peppercorn, M.A. Ulcerative colitis: current treatment strategies and future prospects. Therap. Adv. Gastroenterol., 2009 2, 99-108.
11. Stowe, S.P.; Redmond, S.R.; Stormont, J.M.; Shah, A.N.; Chessin, L.N.; Segal, H.L.; Chey, W.Y. An epidemiologic study of inflammatory bowel disease in Rochester, New York. Hospital incidence. Gastroenterology, 1990, 98(1), 104-110.
12. Loftus, C.G.; Loftus, E.V.; Harmsen, W.S.; Zinsmeister, A.R.; Tremaine, W.J.; Melton, L.J.; Sandborn, W.J. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm. Bowel. Dis., 2007, 13, 254-261.
13. Marchioni, B.R.; Kane, S. Current approaches to the management of new-onset ulcerative colitis. Clin. Exp. Gastroenterol., 2014, 7, 111-132.
14. Darfeuille-Michaud, A.; Boudeau, J.; Bulois, P.; Neut, C.; Glasser, A.L.; Barnich, N.; Bringer, M.A.; Swidsinski, A.; Beaugerie, L.; Colombel, J.F. High prevalence of adherentinvasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology, 2004, 127, 412-421.
15. Comito, D.; Cascio, A.; Romano, C. Microbiota biodiversity in inflammatory bowel disease. Ital. J. Pediatr., 2014, 40, 32.
16. Read, N.W.; Kreis, G.J.; Read, M.G.; Santa Ana, C.A.; Morawski, S.G.; Fordtran, J.S. Chronic diarrhea of unknown origin. Gastroenterology, 1980, 78, 264-271.
17. Ingle, S.B.; Adgaonkar, B.D.; Ingle, C.R. Microscopic colitis: Common cause of unexplained nonbloody diarrhea. World J. Gastrointest. Pathophysiol., 2014, 5, 48-53.
18. Rasmussen, M.A.; Munck, L.K. Systematic review: are lymphocytic colitis and collagenous colitis two subtypes of the same disease -microscopic colitis? Aliment. Pharmacol. Ther., 2012, 36, 79-90.
19. Thorsen, A.J. Noninfectious colitides: collagenous colitis, lymphocytic colitis, diversion colitis, and chemically induced colitis. Clin. Colon Rectal. Surg., 2007, 20, 47-57.
20. Andersen, T.; Andersen, J.R.; Tvede, M.; Franzmann, cM.B. Collagenous colitis: are bacterial cytotoxins responsible? Am. J. Gastroenterol., 1993, 88, 375-377.
21. Ballinger, A. Adverse effects of nonsteroidal antiinflammatory drugs on the colon. Curr. Gastroenterol. Rep., 2008, 10, 485-489.
22. Bohr, J.; Tysk, C.; Eriksson, S.; Abrahamsson, H.; Jarnerot, G. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut, 1996, 39, 846-851.
23. Riddell, R.H.; Tanaka, M.; Mazzoleni, G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut, 1992, 33, 683-686.
24. Thomson, R.D.; Lestina, L.S.; Bensen, S.P.; Toor, A.; Maheshwari, Y.; Ratcliffe, N.R. Lansoprazole-associated microscopic colitis: a case series. Am. J. Gastroenterol., 2002, 97, 2908-2913.
25. Chande, N.; McDonald, J.W.; MacDonald, J.K. Interventions for treating collagenous colitis. Cochrane. Database. Syst. Rev., 2008, CD003575.
26. Chatelain, D.; Mokrani, N.; Flejou, J.F. Microscopic colitis: collagenous colitis and lymphocytic colitis. Ann. Pathol., 2007, 27, 448-458.
27. Madisch, A.; Morgner, A.; Stolte, M.; Miehlke,S. Investigational treatment options in microscopic colitis. Expert. Opin. Investig. Drugs, 2008, 17, 1829-1837.
28. Schiller, L.R. Diagnosis and management of microscopic colitis syndrome. J. Clin. Gastroenterol., 2004, 38, S27-S30.
29. Baert, F.; Schmit, A.; D'Haens, G.; Dedeurwaerdere, F.; Louis, E.; Cabooter, M.; De Vos, M.; Fontaine, F.; Naegels, S.; Schurmans, P.; Stals, H.; Geboes, K.; Rutgeerts, P.; Belgian IBD Research Group.; Codali Brussels. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology, 2002, 122, 20-25.
30. Miehlke, S.; Heymer, P.; Bethke, B.; Bastlein, E.; Meier, E.; Bartram, H.P.; Wilhelms, G.; Lehn, N.; Dorta, G.; DeLarive, J.; Tromm, A.; Bayerdorffer, E.; Stolte, M. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology, 2002, 123, 978-984.
31. Sobczak, M.; Wlazłowski, M.; Zatorski, H.; Sałaga, M.; Fichna, J. Current overview of colitis-associated colorectal cancer. Cent. Eur. J. Biol., 2014, 9, 1022-1029.
32. Ahmed, F.E. Effect of diet, life style, and other environmental/chemopreventive factors on colorectal cancer development, and assessment of the risks. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev., 2004, 22, 91-147.
33. Forbes, G.M. Colorectal cancer screening tests: pros and cons, and for whom?. Expert. Rev. Gastroenterol. Hepatol., 2008, 2, 197-205.
34. Tarraga Lopez, P.J.; Albero, J.S.; Rodriguez-Montes, J.A. Primary and secondary prevention of colorectal cancer. Clin. Med. Insights. Gastroenterol., 2014, 7, 33-46.
35. Drake, P.L.; Hazelwood, K.J. Exposure-related health effects of silver and silver compounds: a review. Ann. Occup. Hyg., 2005, 49, 575-585.
36. Morones, J.R.; Elechiquerra, J.L.; Camacho, A.; Holt, K.; Kouri, J.B.; Ramirez, J.T.; Yacaman, M.J. The bactericidal effect of silver nanoparticles. Nanotechnology, 2005, 16, 2346-2353.
37. Pal, S.; Tak, Y.K.; Song, J.M. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl. Environ. Microbiol., 2007, 73, 1712-1720.
38. A.Bourcet. Biological assesment of medical devices containing nanomaterials -Scientific Report. http://ansm.sante.fr/Activites/Surveillance-du-marche-desdispositifs-medicaux-et-dispositifs-medicaux-de-diagnosticin-vitro-DM-DMDIV/Dispositifs-medicaux-Operations-devaluation-et-de-controle-du-marche/Dispositifs-medicaux-Operations-d-evaluation-et-de-controle/Evaluation-biologique-des-dispositifs-medicaux-contenant-des-nanomateriaux (Accessed June 10, 2015).
39. Stevens, K.N.; Crespo-Biel, O.; van den Bosch, E.E.; Dias, A.A.; Knetsch, M.L.; Aldenhoff, Y.B.; van der Veen, F.H.; Maessen, J.G.; Stobberingh, E.E.; Koole, L.H. The relationship between the antimicrobial effect of catheter coatings containing silver nanoparticles and the coagulation of contacting blood. Biomaterials, 2009, 30, 3682-3690.
40. Poon, V.K.;Burd, A. In vitro cytotoxity of silver: implication for clinical wound care. Burns, 2004, 30, 140-147.
41. Dunn, K.; Edwards-Jones, V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns, 2004, 30 (Suppl 1), S1-S9.
42. Trop, M.; Novak, M.; Rodl, S.; Hellbom, B.; Kroell, W.; Goessler, W. Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J. Trauma, 2006, 60, 648-652.
43. Nadworny, P.L.; Wang, J.; Tredget, E.E.; Burrell, R.E. Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model. Nanomedicine, 2008, 4, 241-251.
44. Cha, K.; Hong, H.W.; Choi, Y.G.; Lee, M.J.; Park, J.H.; Chae, H,K.; Ryu, G.; Myung, H. Comparison of acute responses of mice livers to short-term exposure to nanosized or micro-sized silver particles. Biotechnol. Lett., 2008, 30, 1893-1899.
45. Chen, X.; Schluesener, H.J. Nanosilver: a nanoproduct in medical application. Toxicol. Lett., 2008, 176, 1-12.
46. Singh, N.; Manshian, B.; Jenkins, G.J.; Griffiths, S.M.; Williams, P.M.; Maffeis, T.G.; Wright, C.J.; Doak, S.H. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials, 2009, 30, 3891-3914.
47. Bhol, K.C.; Schechter, P.J. Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis. Dig. Dis. Sci., 2007, 52, 2732-2742.
48. Sibbald, R.G.; Contreras-Ruiz, J.; Coutts, P.; Fierheller, M.; Rothman, A.; Woo, K. Bacteriology, inflammation, and healing: a study of nanocrystalline silver dressings in chronic venous leg ulcers. Adv. Skin Wound. Care, 2007, 20, 549-558.
49. Bhol, K.C.; Schechter, P.J. Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br. J. Dermatol., 2005, 152, 1235-1242.
50. Morrill, K.; May, K.; Leek, D.; Langland, N.; Jeane, L.D.; Ventura, J.; Skubisz, C.; Scherer, S.; Lopez, E.; Crocker, E.; Peters, R.; Oertle, J.; Nguyen, K.; Just, S.; Orian, M.; Humphrey, M.; Payne, D.; Jacobs.; Waters, R.; Langland, J. Spectrum of antimicrobial activity associated with ionic colloidal silver. J. Altern. Complement Med., 2013, 19, 224-231.
51. Tien, D.C.; Tseng, K.H.; Liao, C.Y.; Tsung, T.T. Colloidal silver fabrication using the spark discharge system and its antimicrobial effect on Staphylococcus aureus. Med. Eng Phys., 2008, 30, 948-952.
52. Li, C.; Wang, X.; Chen, F.; Zhang, C.; Zhi, X.; Wang, K.; Cui, D. The antifungal activity of graphene oxide-silver nanocomposites. Biomaterials, 2013, 34, 3882-3890.
53. Kim, H.J.; Park, H.J.; Choi, S.H. Antimicrobial action effect and stability of nanosized silica hybrid Ag complex. J. Nanosci. Nanotechnol., 2011, 11, 5781-5787.
54. Mahltig, B.; Cheval, N.; Astachov, V.; Malkoch, M.; Kaase, K.; Fahmi, A. Hydroxyl functional polyester dendrimers as stabilizing agent for preparation of colloidal silver particlesGCoa study in respect to antimicrobial properties and toxicity against human cells. Colloid Polym. Sci., 2012, 290, 1413-1421.
55. Monteiro, D.C.; Phillips, R.M.; Crossley, B.D.; Fielden, J.; Willans, C.E. Enhanced cytotoxicity of silver complexes bearing bidentate N-heterocyclic carbene ligands. Dalton Trans., 2012, 41, 3720-3725.
56. Ramachandran, L.; Krishnan Nair, K. Ch. therapeutic potentials of silver nanoparticle complex of α-lipoic acid. Nanotechnol. Nanomater., 2011, 1(2), 17-24.
57. Modak, S.M.; Sampath, L.; Fox, C.L. Jr.; Benvenisty, A.; Nowygrod, R.; Reemstmau, K. A new method for the direct incorporation of antibiotic in prosthetic vascular grafts. Surg. Gynecol. Obstet., 1987, 164, 143-147.
58. Langer, R. Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Acc. Chem. Res., 2000, 33, 94-101.
59. Conde, J.; de la Fuente, J.M.; Baptista, P.V. Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea? Front Pharmacol., 2013, 4, 134.
60. Gibson, J.D.; Khanal, B.P.; Zubarev, E.R. Paclitaxelfunctionalized gold nanoparticles. J. Am. Chem. Soc., 2007, 129, 11653-11661.
61. Conde, J.; de la Fuente, J.M.; Baptista, P.V. In vitro transcription and translation inhibition via DNA functionalized gold nanoparticles. Nanotechnology, 2010, 21, 505101.
62. Conde, J.; Ambrosone, A.; Sanz, V.; Hernandez, Y.; Marchesano, V.; Tian, F.; Child, H.; Berry, C.C.; Ibarra, M.R.; Baptista, P.V.; Tortiglione, C.; de la Fuente, J.M. Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano, 2012, 6, 8316-8324.
63. Conde, J.; Rosa, J.; de la Fuente, J.M.; Baptista, P.V. Goldnanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events. Biomaterials, 2013, 34, 2516-2523.
64. Hainfeld, J.F.; Slatkin, D.N.; Smilowitz, H.M. The use of gold nanoparticles to enhance radiotherapy in mice. Phys. Med. Biol., 2004, 49, N309-N315.
65. Tisato, F.; Marzano, C.; Porchia, M.; Pellei, M.; Santini, C. Copper in diseases and treatments, and copper-based anticancer strategies. Med. Res. Rev., 2010, 30, 708-749.
66. Daniel, K.G.; Harbach, R.H.; Guida, W.C.; Dou, Q.P. Copper storage diseases: Menkes, Wilsons, and cancer. Front. Biosci., 2004, 9, 2652-2662.
67. Daniel, K.G.; Gupta, P.; Harbach, R.H.; Guida, W.C.; Dou, Q.P. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem. Pharmacol., 2004, 67, 1139-1151.
68. Marzano, C.; Pellei, M.; Tisato, F.; Santini, C. Copper complexes as anticancer agents. Anticancer Agents Med. Chem., 2009, 9, 185-211.
69. Fox, C.L. Jr. Pharmacology and clinical use of silver sulfadiazine and related topical antimicrobial agents. Pahlavi. Med. J., 1977, 8, 45-64.
70. Fox, C.L. Jr.; Modak, S.; Stanford, J.W.; Fox, P.L. Metal sulfonamides as antibacterial agents in topical therapy. Scand. J. Plast. Reconstr. Surg., 1979, 13, 89-94.
71. Fox, C.L. Jr.; Rao, T.N.; Azmeth, R.; Gandhi, S.S.; Modak, S. Comparative evaluation of zinc sulfadiazine and silver sulfadiazine in burn wound infection. J. Burn Care Rehabil., 1990, 11, 112-117.
72. Maier-Hauff, K.; Ulrich, F.; Nestler, D.; Niehoff, H.; Wust, P.; Thiesen, B.; Orawa, H.; Budach, V.; Jordan, A. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol., 2011, 103, 317-324.
73. Staves, B. Pilot study of Aurolase™ therapy in refractory and/or recurrent tumors of the head and neck. http://clinicaltrials.gov/ct2/show/related/NCT00848042?ter m=auroshells&rank=1 ( Accessed June 10 2015)
74. El-Sayed, I.H. Nanotechnology in head and neck cancer: the race is on. Curr. Oncol. Rep., 2010, 12, 121-128.
75. Scaldaferri, F.; Gerardi,V.; Lopetuso, L.R.; Del Zompo,F.; Mangiola, F.; Boškoski, I.; Bruno, G.; Petito, V.; Laterza, L.; Cammarota, G.; Gaetani, E.; Sgambato, A.; Gasbarrini, A. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed. Res. Int., 2013, 2013, Article ID 435268.
76. Sheh, A.; Fox, J.G. The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis. Gut Microbes., 2013, 4, 505-531.
77. Chalew, A.T.; Schwab, K. Toxicity of commercially available engineered nanoparticles to Caco-2 and SW480 human intestinal epithelial cells. Cell Biol. Toxicol., 2013, 29, 101-116.
78. Mukherjee, P.; Bhattacharya, R.; Bone, N.; Lee, Y.K.; Patra, C.R.; Wang, S.; Lu, L.; Secreto, C.; Banerjee, P.C.; Yaszemski, M.J.; Kay, N.E.; Mukhopadhyay, D.; Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J. Nanobiotechnol., 2007, 5, 4.
79. Morones-Ramirez, J.R.; Winkler, J.A.; Spina, C.S.; Collins, J.J. Silver enhances antibiotic activity against gramnegative bacteria. Sci. Transl. Med., 2013, 5, 190ra81.
80. Morones, J.R.; Elechiguerra, J.L.; Camacho, A.; Holt, K.; Kouri, J.B.; Ramirez, J.T.; Yacaman, M.J. The bactericidal effect of silver nanoparticles. Nanotechnology, 2005, 16, 2346-2353.
81. Pal, S.; Tak, Y.K.; Song, J.M. Does the Antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? a study of the gram-negative bacterium Escherichia coli. Appl. Environ. Microbiol., 2007, 73, 1712-1720.
82. Shrivastava, S.; Bera, T.; Roy, A.; Singh, G.; Ramachandrarao, P.; Dash, D. Characterization of enhanced antibacterial effects of novel silver nanoparticles. Nanotechnology, 2007, 18, 225103.
83. Yoon, K.Y.; Hoon Byeon, J.; Park, J.H.; Hwang, J. Susceptibility constants of Escherichia coli and Bacillus subtilis to silver and copper nanoparticles. Sci. Total Environ., 2007, 373, 572-575.
84. Chiao, S.H.; Lin, S.H.; Shen, C.I.; Liao, J.W.; Bai, I.J.; Wei, J.C.; Tseng, L.P.; Hsu, S.H.; Lai, P.S.; Lin, S.Z.; Lin, J.J.; Su, H.L. Efficacy and safety of nanohybrids comprising silver nanoparticles and silicate clay for controlling Salmonella infection. Int. J. Nanomed., 2012, 7, 2421-2432.
85. Arora, S.; Jain, J.; Rajwade, J.M.; Paknikar, K.M. Interactions of silver nanoparticles with primary mouse fibroblasts and liver cells. Toxicol. Appl. Pharmacol., 2009, 236, 310-318.
86. Hsin, Y.H.; Chen, C.F.; Huang, S.; Shih, T.S.; Lai, P.S.; Chueh, P.J. The apoptotic effect of nanosilver is mediated by a ROS-and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells. Toxicol. Lett., 2008, 179, 130-139.
87. Mookerjee, A.; Mookerjee Basu, J.; Dutta, P.; Majumder, S.; Bhattacharyya, S.; Biswas, J.; Pal, S.; Mukherjee, P.; Raha, S.; Baral, R.N.; Das, T.; Efferth, T.; Sa, G.; Roy, S.; Choudhuri, S.K. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis. Clin. Cancer Res., 2006, 12, 4339-4349.
88. Sawosz, E.; Binek, M.; Grodzik, M.; Zielińska, M.; Sysa, P.; Szmidt, M.; Niemiec, T.; Chwalibog, A. Influence of hydrocolloidal silver nanoparticles on gastrointestinal microflora and morphology of enterocytes of quails. Arch. Anim. Nutr., 2007, 61, 444-451.
89. Walczak, A.P.; Fokkink, R.; Peters, R.; Tromp, P.; Herrera Rivera, Z.E.; Rietjens, I.M.; Hendriksen, P.J.; Bouwmeester, H. Behaviour of silver nanoparticles and silver ions in an in vitro human gastrointestinal digestion model. Nanotoxicology, 2012, 7, 1198-1210.